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Summary: An enzyme immunoassay for the determination of human urinary kallikrein has been developed and is
compared with other human urinary kallikrein assays such äs radioimmunoassay, dog blood pressure assay, rat uterus
test after kinin liberation and synthetic Substrate2) tests (AcPheArgOEt and S-2266). The usable ränge of the Standard
curve is from 0.05 to 12 ng kallikrein per test. The intfaassay coefficient of Variation is between 2 and 4%, the inter-
assay coefficient of Variation is between 4 and 12%, and the recovery of auth^ntic kallikrein added to urine samples
is 95%. Human saliva and human pancreatic kallikrein show the same binding curves äs purified human urinary kalli-
krein. Kallikrein from urine of rats, dogs and rabbits äs well äs boar acrosin and pig pancreatic kallikrein, bovine
trypsin and chymotrypsin show no cross-reactivity.
Enzymimmunoassay für menschliches Härnkallikrein
Bestimmung von menschlichem Harnkattikrein, III
Zusammenfassung: Ein Enzymimmunoassay zur Bestimmung menschlichen Harnkallikreins wurde entwickelt und mit
anderen Hamkallikrein-Bestimmungsmethoden wie Radioimmunoassay, Hundeblutdruck-Test, Rattenuterustest nach
Kinirifreisetzung und Aktivitätstest mit synthetischen Substraten2) (AcPheArgOEt und S-2266) verglichen. Der zur
Bestimmung von Härnkallikrein verwendbare Bereich auf der Standardkurve lag zwischen 0,05 und 12 ng pro Test. Der
Intraassaykoeffizient lag zwischen 2 und 4%, der Interassaykoeffizient zwischen 4 und 12% und die Wiederfmdungs-
rate von Härnkallikrein, das zu Harnen zugegeben wurde, bei 95%. Menschlicher Speichel und Pankreas-Kallikrein
ergaben Bindüngskurven, die mit der für reines Harnkallikrein erhaltenen Bindungskurve identisch waren. Kallikrein aus
Harn von Ratten, Hunden und Kaninchen, Schweine^Akrosin und Schweinepankreas-Kallikrein sowie Trypsin und
Chymotrypsin des Rindes zeigten keine Kreüzfeaktion.
Introduction lysis of synthetic Substrates, e.g. N^-benzoyl-Z-arginine
Detenninationoftiss^ ?^5* ^
urine and body fluids is öf special interest because of its Ar*OEt ^ A^f > ™ f™ nOt SpeClfk ^  SenS"
postulated physiölogical role in kidney function and *» »°^ ^ r ""wj detennmation in tissue
blöod pressure regulation, fertüization processes, glucose «traetus or other body flu^s; IJ addition, they do not
metaboüsm and intestinal absorption (l, 2). dlow the ^ e^rement of kaUikrem m the presence of
inhibitors i.e. in the form of the enzyme-inhibitor
Various methods for the determination of urinary complex (5—10).
kallikreiri are available at present. Some assays such äs
the biological assay .(reduction of dog blood pressure *) l. = i.e. (23); II. = I.e. (11)
after intravenous urine injection (3)) and the kinin- 2) Abbreviations:
Hberating test (kallikrein-mduced kinin liberation from AcPheArgOEt: ^o^^hwylal.^l.L^iginto
Wninogens and determination of the kiniris by biological
 DValLeuArgNHNp: D-valvl-^-leucyl-L-arginine-p-nitro-
assays, immunoassays or high performance liquid chroma- anüide (= S-2266 from Kabi)
tography (4)) are cuiiibersome and not suitable for
 ABTS 2,2'-azino-bis o-ethyi-benzthiazoline-
routine purposes. Other methods based on the hydro- 6-sulfonate)
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Recently, a radioimmunoassay has been developed for
the determination of human urinary kallikrein (11) and
since that time this assay has become a common method
for the determination of human tissue kallikrein. How-
ever, general problems of the radioimmunoassay such äs
special and expensive equipment for radioactive measure-
ments and the disposal of radioactive waste stiinulated
the development of alternative but also highly sensitive
immunoassays. This report describes an enzyme immuno-
assay for human tissue kallikrein allöwing estimation
of kallikrein levels äs low äs 0.5 §/1 in a reasonably
short time (5 hours incubation time).
Material and Methods
Human urinary kallikrein, used äs a Standard in the enzyme
immunoassay, was purified äs described (12). Human pancreatic
kallikrein was isolated äs described by Hofmann et al. (13).
Horseradish peroxidase (EC 1.11.1.7; grade 1) and bovine
trypsin and chymotrypsin were products of Boehringer,
Mannheim. Boar acrosin was kindly provided by Müller-Esterl
& Fritz (14), human high molecular weight kininogen by
Dittmann et al. (15)\ Pig pancreatic kallikrein was a gift of
Bayer AG, Wuppertal. Bovine serum albumin was purchased
from Behiingwerke AG, Marburg/Lahn. Bradykinin was a
product of Bachern AG, Bubendorf, Switzerland. AcPheArgOEt2)
was synthesized äs described by Fiedler et al. (8). DValLeuArg-
NHNp2) was purchased from Kabi AB, Mölndal, Sweden.
Tween 20 was a product of Serva AG. Microtiter plates
M 129 B were purchased from Dynatech, Denkendorf, West-
Germany.
Antibody production in rabbits was performed äs described
byMann et al. (11). IgG fractions were isolated according to
Steinbuch & Audran (16).
Sample collection
24-hour urine samples of male and female healthy volunteers
were collected. The urines were dialysed against running
water for 24 h.-Saliva obtained by selective catherization of
the glandular duct was collected before and after oral ad-
ministration of 2 ml citric acid (100 g/l), freeze-dried and
stored at - 20 °C. Pancreatic juice was collected by a
duodenal catheter in a X-ray monitored position. Samples
of serum and seminal plasma were obtained from healthy volun-
teers.
Buffers
Buffer A
Buffer B
Buffer C
Buffer D
15 mmol/1 Na2CO3, 350 mmol/1 NaHCO3,
0.2g/lNaN3,pH9.6.
1.5 mmol/1 KH2PO4, 8 mmol/1 Na2HPO4,
2.7 mmol/1 KC1, 150 mmol/1 NaCl, 0.5 g/l,
Tween 20, pH 7.4.
1.5 mmol/1 KHaPO4, 8 mmol/1 Na2HPO4,
2.7 mmol/1 KC1, 150 mmol/1 NaCl, 0.5 g/l,
Tween 20, 20 g/l bovine serum albumin, pH 7.4.
100 mmol/1 citric acid, 100 mmol/1 K2HPO4, pH 4.0.
Kallikrein activity
Human kallikrein activity was measured using DValLeuArg-
NHNp and AcPheArgOEt äs Substrates (17). Kallikrein-induced
kiriin liberation from human urinary kallikrein by radioimmuno-
assay was performed according toMann et al. (11).
Biological assay
Kinin activity was assayed by the rat Uterus assay äs described
by Mann et al. (10). Bradykinin served äs reference for kinin
activity determination. Dog blood pressure assay was performed
äs described by Frey et al. (3).
Coupling of peroxidase to IgG
Preparatipn of peroxidase IgG conjugate was performed äs
described by Nakane & Kawoi (18). After gel filtration on
Sephadex G-100 the anti-human urinary kälfikrein-IgG peroxi-
dase conjugate was diluted l :50 with buffer C before being
used for the enzyme immunoassay.
Enzyme immunoassay conditions
Microtiter plates were coated with the sapie anti-human urinary
kallikrein-IgG solution (IgG 10 mg/1 buffer) (0.2 ml per well)
äs used for the peroxidase IgG conjugate at 4 °C over night.
The plates were then washed vigorously (3 times) in buffer B.
Human urinary kallikrein Standard samples and test samples were
diluted with buffer C. Of these samples 0.2 ml were added to the
wells and the plates were incubated at 37 °C for 3 h in order to
bind the kallikrein to the solid-phase fixed antibodies. After ineu-
bation, the plates were washed (3 times) with buffer B, 0.2 ml of
the anti-human urinary kallikrein-IgG peroxidase conjugate was
added to each well, and the plates were incubated again at 37 °C
for 2 h; After washing peroxidase activity was measured äs
described by Anaokar et al. (19) by addition of 0.2 ml working
Substrate solution (stock Substrate consisted of 200 mg ABTS?)
dissolved in 10 ml water). To prepare working Substrate, 0.5 ml
stock solft. was added to 9.5 ml buffer D and 0.2 ml H2O2
solution (H2O2, 300 g/kg, diluted 0.6 ml/l) was added and the
plates were incubated for 30 mifi at room temperature. There-
after, the reaction was stopped by addition of 0.05 ml sodium
azide (10 g/l). The absorption was read photometricaliy at
405 nm with a Microelisa®-reader AM 115 from Dynatech,
Denkendorf, West-Germany. Bäckgfouiid generally ranged from
^405 nm = 0.02 to 0.08. In each test a Standard concentration
curve with purified human urinary kallikrein was inclüded.
Standard curves were constructed by plotting the fraction of
absorbance at 405 nm, A - N/A0 - N (A: absorbance, AQ:
maximal absorbance obtained with excess human urinary
kallikrein, N: absorbance of the blank) against the dose of
human urinary kallikrein in a logit-log mpde or in a linear-log
mode.
A scheme of the incubation conditions is shqwn in Table 1.
Tab. 1. Scheme of human uririary kallikrein (HUK) enzyme
immunoassay. Samples were in triplicate.
Anti,HUK-IgG (10 mg/1)
Standard or sample
Sample
(ml)
0.20
15hat4°C
0.20
Blank
(ml)
0.20
Buffer C
Anti-HUK-IgG peroxidase con-
jugate, dil. 1:50
Substrate solution
Sodium azide (10 g/l)
0.20
3 ha t 37 °C
0.20 0.20
2 hat 37 °C
0.20 0.20
30minat22°C
0.05 0.05
absorbance read at 405 nm
Results
Concentration ofthe solid-phase IgG
Th^ least amount of IgG reqüired to coät the micfö-
titer plates was determined from Standard curves of
data obtained with plates treated wit&concentrations
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Fig. 1. Evaluation of the optimal concentration of the solid-
phase antibody. Dose response curves for human urinary
kallikrein obtained with microtiter plate wells coated
with l mg (·—·), 2.5 mg (*—A), 5
 mg (·—·) and
10 mg (o—o) of anti-human urinary kallikrein-IgG per
liter.
jugate at which optimal absorbance at 405 nm occurred,
this conjugate dilution was chosen for the assay.
Time and temperature dependence ofthe antigen anti-
body reactions
To determine the optimal incubation conditions for the
enzyme immunoassay the time and temperature depend-
ence of the first incubation, the binding of human
urinary kallikrein to the solid-phase fixed antibody,
was studied at 22 and 37 °C. The highest binding rate
was observed at 37 °C, where equilibrium was reached
after 3 hours (fig. 2a). The optimal time and temper-
ature required for the second reaction, binding of anti-
human urinary kallikrein-IgG peroxidase conjugate to
solid-phase immunglobulin-fixed human urinary kalli-
krein, was simüarily determined. As shown in figure 2b,
this time equilibrium was reached after 2 hours at
37 °C. Concentration ofthe IgG-solution used for
coating was 10 mg/1, and the anti-human urinary kalli-
kreinJgG peroxidase conjugate dilution was 20-fold.
of IgG ranging from l to 10 mg/1. As seeü in figure l,
the Standard curves were identical for IgG concentra-
tions between 10 and 5 mg/1 whereas Standard curves
obtained with IgG concentrations lower then 5 rrig/1
showed a decreased binding of human urinary kalli-
krein. Hence, we decided to use an IgG concentration
of 10 mg/1 för the assay. Anti-human urinary kallikrein-
IgG peroxidase conjugate dilution in the experiment
was fixed at a 50-fold dilution.
Anti^human urinary kallikrein-IgG peroxidase conjugate
dilution
The optimal dilution of the conjugate was deterrnined
from a Standard eürve obtained with microtiter plates
coated with an IgG solution of 10 rrig/1 arid conjugate
diluted 100,, 50-, 20- and 10-fÖld with büffer C. As the
SO-fpld dilution was the highest dilution of the con-
Standard curves and sensitivity
The Standard curve was consistently linear for human
urinary kallikrein concentrations between 0.25 and
60 g/l under routine conditions (fig. 3). The sensitivity
of an enzyme immunoassay can be defined äs "the
smallest amount of antigen giving a response which is
distinguishable from the response in the absence of
antigen" (20). The lowest concentration of human
urinary kallikrein that produced a response greater than
that caused in the absence of human urinary kallikrein
was 0.25 Mg/1, which corresponds to 50 pg per well.
Precision
The intraassay coefficient of Variation (N = 10) was
2—4% för human urinary kallikrein (ränge 0.25 to
64 Mg/1). The interassay coefficient of Variation of
identical samples (N ^  10) containing 1,4, 16, 64 /ig/l
was 4—12%.
l»
2 3
t lh]
2 3 4
t [h]
Fig. 2. incubaUon time and temperature dependence of the first (a) and second (b) reaction. Dose response curves for human urinary
kallikrein were obtained by incubating Standard (10 Mg/1) at room temperature (o) and 37 °C (·).
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Fig. 3. Dose response curves of purified human urinary kallikrein and human pancreatic källikrein in the human urinary kaflikrein
enzyme immunoassay, ·—·, Standard human urinary kallikrein, A^-A, human päncreatic kallikrein (2.7 mg/1).
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Fig. 4. Dose response curves of human urinary kallikrein and human body fluids in the human urinary kallikrein enzyme immuno·^
assay; ·—·, Standard human urinary kallikrein, o—o, pancreatic juice, ·—·, saliva (500 |/ ), *—+> urine, *--—A, serum,
*—*, seminal plasma.
Speciflcity
Cross-reaction of other serine proteinases with anti-
human urinary kallikrein-IgG was tested under the
given immunoassay conditions. A cross-reaction was not
observed with bovine trypsin and chymotrypsin, pig
pancreatic kallikrein, boar acrosin and urine from
rat, dog and rabbit. In the human samples investigated,
immunologically active material was found in pancreatic
juice, saliva, urine, serum and seminal plasma. Suitable
dose-response curves are shown in figüre 4.
Recovery fest
Recovery tests in which three different quantities of
purified human urinary kallikrein were added to antigen-
free rat urine showed a good precision of the assay. The
data are listed in table 2.
Tab. 2. Recovery test.
Human urinary kallikrein
Added
(Mg/0
20
10
5
Recovered
(Mg/D
19.0 ± 0.46
10.5 ± 0.12
5.1 ± 0.06
N
10
10
10
Recovery
(%)
95 ± 2.3
105 ± 1.2
102 ± 1.2
Stability ofthe microtiter plätes coated with anti-
human urinary kallikrein-IgG
Microtiter plätes coated with anti-human urinary kalli-
krein-igG were air-dried and stored at 4 °C in sealed
plästic bags containing sjlica gel. Identical Standard
curves were obtairied under roütine conditions withiri
a period of 3 weeks after coating. Tliereafter a decrease
of binding was observed. * »
J. Cün. Chem. Clin. Biochem. / Vol. 20,1982 / No. 9
Franke, Rohrschneiderand Geiger: Enzyme immunoassay of human urinary kallikrein 625
Comparison ofthe enzyme immunoassay with other
methods
In order to show the correlation of the enzyme immuno-
assay with other determination methods for human urin-
ary kallikrein, 10 dialysed urine test samples were
measured by different kallikrein assays. As can be seen
from figure 5 the correlation coefficients of the synthetic
Substrate assays with AcPheArgOEt and DValLeuArg-
NHNp, the dog blood pressure assay, the kinin-liberation
assay, the radioimmunoassay of human urinary kallikrein
and the enzyme immunoassay are close to l.
Tab. 3. Comparison of the enzyme immunoassay for human
urinary kallikrein with other assays for human urinary
kallikrein. 10 samples of dialysed urine were measured
by each method.
Assays for
human urinary kallikrein
Correlation coefficients
obtained with human urinary
kallikrein enzyme immuno-
assay
Radioimmunoassay (l 1) 0.9932
Dog blood pressure (3) 0.9643
Kinin liberation (10) 0.9824
Synthetic Substrates
AcPheArgOEt (17) 0.9910
DValLeuArgNHNp (17) 0.9920
Discussion
The sensitive and specific enzyme immunoassay devel-
oped for human urinary kallikrein should be especially
suitable for further studies on the physiological and
pathophysiological rple of tissue kallikreins. As the
different tissue kallikreins in humans are imrnunplogic-
ally indistinguishable (21), this assay ean be used to
detect all of them.
The high specificy of the epzyme imrnünoassay could
be demonstrated by emplpying väriöüs serine protein*
ases. Cross reactivity was not obsefved with bpvine
trypsin and chymotrypsin, boar acrosin and pig
pancreatic kallikrein. Furthermpre, in analögy to
the results obtained by radioimmünoassay of human
urinary kallikreiri (l 1) we mäy expect that human
proteinases pther thäii tissue kallikreins dp not inter*
fere in the enzyme immunoassay.
·»
Dose response curves obtained with immunologieajly
crpss-reäcting rnaterial frpm pancreatic juice, serum
and seminal plasma were not parallel with each other.
These results are in agreement with data obtained using
the radioimmunoassay for human urinary kallikrein
(l 1), exeept for the binding curves for human pan-
creatic juice. This is of interest since purified human
pancreatic kallikrein will gjve parallel curves in the
enzyme immunoassay for human urinary kallikrein.
Explanations for these interferences could be the pre-
sence of:
1) prokallikrein or rnodified kallikrein with imrnuno-
logjcally different properties,
2) other, äs yet uncharacterized, cross-reacting antigens,
and
3) inhibitors in the samples which reduce binding to
antibody due to källikrein-inhibitor complex formation.
Further nonspeeific interferences cannot be excluded at
present. All these questions need to be further investi-
gated and methods for the elimination interference
must be developed.
A number of experiments were undertaken to compare
the enzyme immunoassay with assays established
already for the determination of human urinary kalli-
krein. For this purpose dialysed urine samples from
10 different persons were employed. The results obtained
with the enzyme immunoassay were compared with those
obtained by the dog blood pressure assay, a radioimmuno-
assay for human urinary kallikrein, a rat uterus assay
after kallikrein-induced kinin liberation, and assays with
AcPheArgOEt and DValLeuArgNHNp äs kallikrein
Substrates. The correlation between the synthetic sub-
strate assays, the rat uterus assay after kallikrein-induced
kinin liberation and the radioimmunoassay is more satis-
factory than the correlation obtained by comparison of
dog blood pressure assay and enzyme immunoassay.
Though the correlation coefficient of the results of the
enzyme immunoassay and the dog blood pressure assay is
rather close to l, a considerable scattering of the data is
observed. This is not too surprising, since the coefficient
of Variation of the blood pressure assay for kallikrein is
approximately 20% (22). The excellent correlation, how-
ever between the twp immunoassays indicates the high
validity pf the enzyme immunoassay.
Considerable advantages of the enzyme immunoassay
over the radioimmunoassay are, amorig others, the lack
öf radiation hazards, greater stability of the label,
higher thrpughput and ease of automation. The assay
procedure is simple tp perform in a relatively short time
and requires only small quantities of kallikrein. The
minimal detectable döse is 50 pg per well. Therefore, this
assay offers a precise and feasible test for human urinary
kallikrein, which can be used äs an alternative to the
radioimmunoassay.
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